Sahajanand Medical Technologies IPO Review
Sahajanand Medical Technologies Ltd., an R&D-driven company developing Class III & Class C/D medical devices, plans to raise ₹475 Cr through an IPO.
[Fresh Issue NIL + OFS ₹475 Cr]
Sahajanand medical technologies ipo price: ₹327–₹344 per share
Sahajanand Medical Technologies: History
The Company was initially formed as a partnership firm, M/s Sahajanand Vascular Technoventions, under a partnership deed dated October 25, 1999.
The partnership firm was then converted into a joint stock company and was registered as Sahajanand Medical Technologies Pvt Ltd on October 18, 2001.
The Company changed its name to Sahajanand Medical Technologies Ltd and the RoC issued a fresh certificate of incorporation on May 07, 2021.
ALSO READ: Fusion CX IPO Review
Sahajanand Medical Technologies: Business
Sahajanand Medical Technologies Ltd is a Class III and Class C/D medical devices company with a portfolio of technologically advanced medical devices across
Vascular Intervention (VI), and
Structural Heart Intervention (SH).
The Company’s portfolio of
- VI Products includes coronary intervention products such as coronary stents and coronary balloons,
- SH Products includes Trans-Catheter Aortic Valve (TAVI) and Occluders, and
- Other Products include its own brand of renal stents, peripheral DCBs, and other trading products.
The company has established a strong position in the Indian Drug-Eluting Stent (DES) market, accounting for nearly 25% of total sales volume in FY26.
According to the F&S Report, SMT was the first company globally to receive CE certification for a biodegradable polymer-based paclitaxel-eluting stent (Infinnium) in December 2025.
The Company markets its products in 76 countries through a mix of direct, hybrid, and distributor-led models.
Clinical Foundation
The Company has built a strong clinical foundation for its flagship products, i.e., Supraflex Cruz, Hydra, Pipit, and Cocoon.
This foundation is supported by 72 clinical studies (60 completed and 12 ongoing) across diverse geographies and patient populations.
Manufacturing Facilities
As of the date of this DRHP, the company has three manufacturing facilities, two located in India and one in Thailand.
READ THIS: Atlanta Electricals Ltd (Value Pick Stock October 2026)
Strategies Ahead
Drive revenue growth through penetration and the new product launch.
Developing high-value clinically proven products.
Evaluate opportunities for strategic M&As and entry into large markets.
Focus on improving operational efficiency.
Company Promoters
- Bhargav Dhirajlal Kotadia,
- Dhirajlal Vallabhbhai Kotadia,
- Priyanka Dhirajlal Cohen, and
- Shree Hari Trust.
Refer to Sahajanand Medical Technologies IPO DRHP for more information.
IPO Detail
ipo date: 15 Oct – 19 Oct 2026
Minimum Amount: ₹14,792
Minimum Bid: 43 Shares
Face Value: INR 1 per share
Listing On: NSE, BSE
Financial
Book Running Lead Managers
Avendus Capital,
HSBC Securities and Capital Markets,
Nuvama Wealth Management,
Motilal Oswal Investment Advisors.
CONCLUSION
Considering financial performance and the nature of the business, FinBlab recommends a ‘NEUTRAL’ rating for the Sahajanand Medical Technologies IPO.
Do come back to learn more about “upcoming IPOs”.
======================================================================
Disclaimer: This article is purely for informational purposes.
While much time and effort is made to provide the information, I (Vishal Dalwadi) or FinBlab do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.
